
|Articles|October 1, 2010
Dermatology Times, Digital Edition, October 2010
EHRs, Worth the Hassle? : ‘Meaningful use’ criteria can pose high hurdle for derms Allergan Settles : Drugmaker to pay $600 million to resolve off-label marketing charges Special Report : Hair & Nails
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
UCB Presents 3-Year BE HEARD Trial Results for Bimekizumab in Moderate-to-Severe HS
3
Sagimet and Ascletis Report Positive 52-Week Safety and Efficacy Data for Denifanstat in Acne
4
Kicking Off MOPD 2026 With Lawrence Schachner, MD
5











